Myriad Genetics Stock Price, News & Analysis (NASDAQ:MYGN)

$36.05 0.52 (1.46 %)
(As of 01/16/2018 04:42 AM ET)
Previous Close$35.53
Today's Range$35.31 - $36.44
52-Week Range$15.15 - $37.30
Volume670,500 shs
Average Volume511,222 shs
Market Capitalization$2.50 billion
P/E Ratio24.36
Dividend YieldN/A
Beta0.24

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone+1-801-5843600

Debt

Debt-to-Equity Ratio0.09%
Current Ratio2.34%
Quick Ratio2.06%

Price-To-Earnings

Trailing P/E Ratio24.3581081081081
Forward P/E Ratio34.33
P/E Growth2.29

Sales & Book Value

Annual Sales$771.40 million
Price / Sales3.24
Cash Flow$1.77 per share
Price / Cash20.34
Book Value$11.42 per share
Price / Book3.16

Profitability

Trailing EPS$1.48
Net Income$21.80 million
Net Margins42.59%
Return on Equity39.45%
Return on Assets26.49%

Miscellaneous

Employees2,400
Outstanding Shares69,240,000

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.05. The company earned $190.20 million during the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a net margin of 42.59% and a return on equity of 39.45%. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 earnings per share. View Myriad Genetics' Earnings History.

When will Myriad Genetics make its next earnings announcement?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY18 earnings guidance on Tuesday, November, 7th. The company provided EPS guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.03. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $765.01 million.Myriad Genetics also updated its Q2 guidance to $0.22-0.24 EPS.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2018?

11 Wall Street analysts have issued 1-year price targets for Myriad Genetics' shares. Their forecasts range from $16.00 to $45.00. On average, they anticipate Myriad Genetics' share price to reach $28.90 in the next twelve months. View Analyst Ratings for Myriad Genetics.

What are Wall Street analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)
  • 2. According to Zacks Investment Research, "Over the past three months, Myriad Genetics has been trading above the broader industry. Of late, the company has been observing strong growth in GeneSight and EndoPredict testing revenues. Myriad Genetics has also been witnessing continued year-over-year growth in Hereditary Cancer volumes with pricing matching expectations. We are also upbeat about the favorable GeneSight test results entailing patients with Generalized Anxiety Disorder. Notably, the FDA’s acceptance of supplementary premarket approval application for BRACAnalysis CDx as a companion diagnostic to olaparib for treating HER2 negative metastatic breast cancer patients buoys optimism. On the flip side, operating margin has been affected by a rise in operating expenses. Currency fluctuations and stiff competition are other major headwinds." (12/15/2017)
  • 3. Cowen Inc analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:

  • John T. Henderson M.D., Independent Chairman of the Board
  • Mark C. Capone, President, Chief Executive Officer, Director
  • Mark S. Verratti, President-President Assurex Health
  • Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
  • R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
  • Alexander Ford, President of Myriad Genetic Laboratories, Inc.
  • Ralph L. McDade Ph.D., President of Myriad RBM, Inc
  • Bernard F. Tobin, President of Crescendo Bioscience, Inc
  • Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
  • Gary A. King, Executive Vice President - International Operations

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of Myriad Genetics stock can currently be purchased for approximately $36.05.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.50 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.48 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 S Wakara Way, SALT LAKE CITY, UT 84108-1214, United States. The company can be reached via phone at +1-801-5843600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  459 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myriad Genetics (NASDAQ:MYGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.001.901.901.77
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.90$26.56$24.67$21.83
Price Target Upside: 17.03% downside14.75% downside32.44% downside11.75% downside

Myriad Genetics (NASDAQ:MYGN) Consensus Price Target History

Price Target History for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ:MYGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018BarclaysReiterated RatingHold$30.00HighView Rating Details
1/5/2018BTIG ResearchInitiated CoverageBuy -> Buy$41.00MediumView Rating Details
1/3/2018StephensSet Price TargetBuy$45.00MediumView Rating Details
11/8/2017Deutsche BankBoost Price TargetHold$28.00 -> $30.00N/AView Rating Details
11/8/2017Morgan StanleyBoost Price TargetUnderweight$24.00 -> $26.00N/AView Rating Details
10/2/2017Leerink SwannReiterated RatingMkt Perform -> Market Perform$31.00MediumView Rating Details
9/17/2017CowenReiterated RatingHold$25.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingHold$21.00 -> $23.00HighView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
6/30/2017JPMorgan Chase & Co.Reiterated RatingUnderweight$16.00LowView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
10/10/2016Bank of AmericaReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
3/23/2016Goldman Sachs GroupBoost Price Target$40.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Myriad Genetics (NASDAQ:MYGN) Earnings History and Estimates Chart

Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
11/7/2017Q1 2018$0.21$0.26$183.52 million$190.20 millionViewN/AView Earnings Details
8/8/2017Q4 17$0.26$0.30$193.71 million$200.50 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
11/2/2010Q1 2011$0.23$0.24ViewN/AView Earnings Details
8/10/2010Q4 2010$0.33$0.39ViewN/AView Earnings Details
5/4/2010Q3 2010$0.38$0.33ViewN/AView Earnings Details
2/2/2010Q2 2010$0.34$0.36ViewN/AView Earnings Details
11/3/2009Q1 2010$0.32$0.31ViewN/AView Earnings Details
8/25/2009Q4 2009$0.23$0.37ViewN/AView Earnings Details
5/4/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/3/2009Q2 2009$0.17$0.22ViewN/AView Earnings Details
11/4/2008Q1 2009$0.07$0.15ViewN/AView Earnings Details
8/19/2008Q4 2008($0.12)$0.70ViewN/AView Earnings Details
5/6/2008Q3 2008($0.05)($0.05)ViewN/AView Earnings Details
2/5/2008Q2 2008($0.08)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Myriad Genetics (NASDAQ:MYGN) Earnings Estimates

2018 EPS Consensus Estimate: $0.98
2019 EPS Consensus Estimate: $1.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.19$0.21$0.20
Q2 20183$0.22$0.23$0.23
Q3 20183$0.24$0.26$0.25
Q4 20183$0.29$0.31$0.30
Q1 20193$0.26$0.27$0.27
Q2 20193$0.24$0.28$0.27
Q3 20193$0.29$0.30$0.29
Q4 20193$0.31$0.34$0.32
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Myriad Genetics (NASDAQ:MYGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Myriad Genetics (NASDAQ MYGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Walter Phd GilbertDirectorSell7,500$33.19$248,925.00View SEC Filing  
12/11/2017Heinrich DreismannDirectorSell6,000$33.50$201,000.0033,743View SEC Filing  
11/13/2017Alexander FordInsiderSell3,031$31.64$95,900.84View SEC Filing  
9/1/2017John T HendersonDirectorSell30,000$30.30$909,000.0052,524View SEC Filing  
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.0038,524View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.0049,493View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00146,026View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.0056,720View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.1940,122View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.0095,640View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.0095,640View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.0012,500View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.008,500View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.0010,000View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.0068,384View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.0080,573View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.3270,737View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.6070,737View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.3070,737View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.0067,543View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.4251,473View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.5851,473View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.0051,473View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.0051,473View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.0018,285View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.8018,285View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.2018,285View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00930View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.0047,609View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.0015,084View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.0026,084View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.0026,084View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.0017,165View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.5048,268View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.002,949View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.0047,609View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88324View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.9617,165View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.002,949View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.0017,165View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18324View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.0048,268View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.0047,609View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.0055,656View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.0047,177View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.0055,656View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Myriad Genetics (NASDAQ MYGN) News Headlines

Source:
DateHeadline
AstraZenecas Lynparza Label Now Includes Breast CancerAstraZeneca's Lynparza Label Now Includes Breast Cancer
www.zacks.com - January 15 at 9:34 AM
Myriad Genetics, Inc. (MYGN) Given Average Rating of "Hold" by AnalystsMyriad Genetics, Inc. (MYGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 12 at 5:42 AM
Barclays Reiterates Hold Rating for Myriad Genetics (MYGN)Barclays Reiterates Hold Rating for Myriad Genetics (MYGN)
www.americanbankingnews.com - January 8 at 8:48 AM
Zacks: Analysts Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 MillionZacks: Analysts Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 Million
www.americanbankingnews.com - January 8 at 8:38 AM
Active-Investors: Wired News - Myriad Genetics Announces Expanded Research Collaboration with AstraZenecaActive-Investors: Wired News - Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
www.finanznachrichten.de - January 5 at 9:45 AM
Wired News – Myriad Genetics Announces Expanded Research Collaboration with AstraZenecaWired News – Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
finance.yahoo.com - January 5 at 9:45 AM
Myriad Genetics (MYGN) Coverage Initiated at BTIG ResearchMyriad Genetics (MYGN) Coverage Initiated at BTIG Research
www.americanbankingnews.com - January 5 at 8:54 AM
Stephens Reaffirms "Buy" Rating for Myriad Genetics (MYGN)Stephens Reaffirms "Buy" Rating for Myriad Genetics (MYGN)
www.americanbankingnews.com - January 3 at 4:58 PM
Myriad Genetics Announces Expanded Research Collaboration with AstraZenecaMyriad Genetics Announces Expanded Research Collaboration with AstraZeneca
finance.yahoo.com - January 3 at 8:50 AM
Myriad Genetics Presents Favorable EMBRACA Trial Results - NasdaqMyriad Genetics Presents Favorable EMBRACA Trial Results - Nasdaq
www.nasdaq.com - December 19 at 5:10 PM
Walter Phd Gilbert Sells 7,500 Shares of Myriad Genetics, Inc. (MYGN) StockWalter Phd Gilbert Sells 7,500 Shares of Myriad Genetics, Inc. (MYGN) Stock
www.americanbankingnews.com - December 15 at 6:32 PM
Myriad Genetics (MYGN) Lowered to Hold at Zacks Investment ResearchMyriad Genetics (MYGN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - December 15 at 1:36 PM
Myriad Genetics Rides on Solid Molecular Diagnostics SuiteMyriad Genetics Rides on Solid Molecular Diagnostics Suite
www.zacks.com - December 14 at 9:46 AM
Wired News – Myriad Genetics EMBRACA Trials Show Positive Results for BRACAnalysis CDx(R) Test on Patients with Metastatic Breast Cancer Responding to Pfizers TalazoparibWired News – Myriad Genetics' EMBRACA Trials Show Positive Results for BRACAnalysis CDx(R) Test on Patients with Metastatic Breast Cancer Responding to Pfizer's Talazoparib
finance.yahoo.com - December 14 at 9:46 AM
Myriad Genetics Presents Encouraging EndoPredict Test Data - NasdaqMyriad Genetics Presents Encouraging EndoPredict Test Data - Nasdaq
www.nasdaq.com - December 13 at 5:22 PM
Myriad Genetics Will Ride High On The Success Of Its New Molecular Diagnostic Products In Future Years - Seeking AlphaMyriad Genetics Will Ride High On The Success Of Its New Molecular Diagnostic Products In Future Years - Seeking Alpha
seekingalpha.com - December 13 at 5:22 PM
Myriads BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes ... - GlobeNewswire (press release)Myriad's BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes ... - GlobeNewswire (press release)
globenewswire.com - December 13 at 5:22 PM
Heinrich Dreismann Sells 6,000 Shares of Myriad Genetics, Inc. (MYGN) StockHeinrich Dreismann Sells 6,000 Shares of Myriad Genetics, Inc. (MYGN) Stock
www.americanbankingnews.com - December 12 at 2:38 PM
Boston Scientific Receives FDA Nod for Vercise DBS SystemBoston Scientific Receives FDA Nod for Vercise DBS System
finance.yahoo.com - December 12 at 10:05 AM
Hill-Rom (HRC) Banks on Strategic Buyouts, Competition RifeHill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife
finance.yahoo.com - December 12 at 10:05 AM
Inogen Rides on Solid Product Portfolio Amid Forex WoesInogen Rides on Solid Product Portfolio Amid Forex Woes
finance.yahoo.com - December 12 at 10:05 AM
Omnicells Rising Costs Affect Bottom Line Amid CompetitionOmnicell's Rising Costs Affect Bottom Line Amid Competition
www.zacks.com - December 11 at 5:24 PM
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : December 11, 2017Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : December 11, 2017
finance.yahoo.com - December 11 at 10:23 AM
Cooper Companies (COO) Tops Q4 Earnings & Revenue EstimatesCooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
finance.yahoo.com - December 11 at 10:23 AM
Myriad Genetics Saw Positive Results from GeneSight TrialMyriad Genetics Saw Positive Results from GeneSight Trial
finance.yahoo.com - December 11 at 10:23 AM
NxStage Nx2me Connected Health Improves Home HemodialysisNxStage Nx2me Connected Health Improves Home Hemodialysis
finance.yahoo.com - December 11 at 10:23 AM
Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018
finance.yahoo.com - December 11 at 10:23 AM
Vertex Kalydeco Study Successful in Children Aged 1-2 Years - NasdaqVertex Kalydeco Study Successful in Children Aged 1-2 Years - Nasdaq
www.nasdaq.com - December 9 at 9:42 AM
Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer ... - GlobeNewswire (press release)Myriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer ... - GlobeNewswire (press release)
globenewswire.com - December 9 at 9:42 AM
Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?
finance.yahoo.com - December 8 at 9:39 AM
Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018
finance.yahoo.com - December 8 at 9:39 AM
Varian Halcyon Gets ANVISA Registration, Grows in OncologyVarian Halcyon Gets ANVISA Registration, Grows in Oncology
finance.yahoo.com - December 8 at 9:39 AM
Walgreens Boots Invests in China to Fortify Retail PharmacyWalgreens Boots Invests in China to Fortify Retail Pharmacy
finance.yahoo.com - December 7 at 9:56 AM
Hologic Banks on Molecular Diagnostics, Competition RifeHologic Banks on Molecular Diagnostics, Competition Rife
finance.yahoo.com - December 7 at 9:56 AM
Edwards Lifesciences Buys Harpoon Medical, Expands PortfolioEdwards Lifesciences Buys Harpoon Medical, Expands Portfolio
finance.yahoo.com - December 7 at 9:56 AM
riskScore Expected to Be Major Advancement for Myriad GeneticsriskScore Expected to Be Major Advancement for Myriad Genetics
finance.yahoo.com - December 6 at 9:50 AM
MYGN Is Focusing on a Small Segment of Preventive Care MarketMYGN Is Focusing on a Small Segment of Preventive Care Market
finance.yahoo.com - December 6 at 9:50 AM
Disease-Specific Panels Key to Myriad Genetics’ Growth StrategyDisease-Specific Panels Key to Myriad Genetics’ Growth Strategy
finance.yahoo.com - December 6 at 9:50 AM
Here's Why You Should Invest in PetMed (PETS) Stock NowHere's Why You Should Invest in PetMed (PETS) Stock Now
finance.yahoo.com - December 6 at 9:50 AM
EndoPredict Posted Robust Demand Trends in US in Fiscal 1Q18EndoPredict Posted Robust Demand Trends in US in Fiscal 1Q18
finance.yahoo.com - December 6 at 9:50 AM
Leadership In Hereditary Cancer Testing Will Drive Myriad Genetics Stock In 2018 - Seeking AlphaLeadership In Hereditary Cancer Testing Will Drive Myriad Genetics' Stock In 2018 - Seeking Alpha
seekingalpha.com - December 5 at 5:07 PM
Myriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $188.75 MillionMyriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $188.75 Million
www.americanbankingnews.com - December 5 at 6:48 AM
This Could Be a Solid Growth Driver for Myriad Genetics in 2018This Could Be a Solid Growth Driver for Myriad Genetics in 2018
finance.yahoo.com - December 4 at 5:10 PM
Companion Diagnostics May Be Major Opportunity for Myriad GeneticsCompanion Diagnostics May Be Major Opportunity for Myriad Genetics
finance.yahoo.com - December 4 at 5:10 PM
Zacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Earnings of $0.24 Per ShareZacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Earnings of $0.24 Per Share
www.americanbankingnews.com - December 3 at 11:40 AM
Myriad Genetics (MYGN) Stock Rating Lowered by ValuEngineMyriad Genetics (MYGN) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 12:40 AM
Today’s Research Reports on Trending Tickers: Myriad Genetics and Portola PharmaceuticalsToday’s Research Reports on Trending Tickers: Myriad Genetics and Portola Pharmaceuticals
finance.yahoo.com - December 1 at 5:00 PM
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : December 1, 2017Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : December 1, 2017
finance.yahoo.com - December 1 at 5:00 PM
Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
finance.yahoo.com - December 1 at 5:00 PM
ETFs with exposure to Myriad Genetics, Inc. : December 1, 2017ETFs with exposure to Myriad Genetics, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 5:00 PM

SEC Filings

Myriad Genetics (NASDAQ:MYGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myriad Genetics (NASDAQ:MYGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myriad Genetics (NASDAQ MYGN) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.